The relapse rate of low-risk m3 leukemia cannot be accurately determined and may be related to both the extent of the disease and individual differences. Low-risk m3 leukemia is the low-risk type of acute promyelocytic leukemia, which is the type of leukemia with the best therapeutic effect at present. Through the standardized treatment of all-trans retinoic acid, arsenious acid and chemotherapy (Zoerythromycin), the vast majority of them can be cured, and the complete remission rate of the induction therapy can reach 95%, and the overall survival rate of 5 years can be up to 90%~95%, and only a very small number of patients have relapsed 5 years after the onset of the disease. For all-trans retinoic acid-resistant or high-risk m3 leukemia patients, the relapse rate is relatively high, up to 5%~30%, after relapse, induction therapy can be repeated, and the second relapse can be achieved by autologous transplantation to achieve molecular remission, and if there are many relapses or drug-resistant, allogeneic hematopoietic stem cell transplantation should be carried out. Daily attention should be paid to the prevention of infection, standardized treatment, and attention to observe whether the disease recurs, the treatment should be carried out under the guidance of physicians.